EASTERN PEDIATRIC ONCOLOGY CONSORTIUM

东部儿科肿瘤学协会(EPOC)由 年，西奈山学校儿科血液科/肿瘤科 耶鲁大学医学院医学院(MSSM) 马里兰医学院(UMSM)和马萨诸塞大学 医学院(UMMS)正式确立了一位历史悠久的知识分子 四位首席调查员之间的关系 机构。EPOC存在的理由是基于 期待我们在POG内部合作的四个机构将 与我们继续运作时相比，对集团的贡献更大 分开的。集团的长远目标是利用我们的 在基础和临床药理学、流式细胞术、 神经母细胞瘤和骨髓的细胞和分子生物学 移植。具体来说，我们(L)将开发和参与新的 神经母细胞瘤和其他肿瘤的生物学治疗方法 儿童胚胎性肿瘤。具体的试点研究将包括一个阶段 我研究硝酸镓，9-顺式维甲酸的第一阶段研究，以及 神经母细胞瘤基于细胞周期的新治疗方法 生长因子拮抗剂的化学增敏作用。(二)增强小众意识 参与POG研究，特别是第一阶段研究。(3) 继续在POG领域提供药理学方面的领导， 神经母细胞瘤、骨肿瘤、骨髓移植和非何杰金氏病 淋巴瘤(4)参与POG的行政职能 骨髓移植、新药和药理学领域 非霍奇金淋巴瘤。

The Eastern Pediatric Oncology Group Consortium (EPOC) consisting of the Division of Pediatric Hematology/Oncology of the Mount Sinai School of Medicine (MSSM), Yale University School of Medicine (YUSM), University of Maryland School of Medicine (UMSM), and University of Massachusetts Medical School (UMMS) formalizes a long standing intellectual relationship between the Principal Investigators of the four institutions. The rationale for the existence of EPOC rests upon the expectation that our four institutions working together within POG will contribute more to the group than would occur if we continued to function separately. The long term objectives of the group are to make use of our scientific expertise in basic and clinical pharmacology, flow cytometry, cellular and molecular biology of neuroblastoma and bone marrow transplantation. Specifically, we will (l) develop and participate in new biologically based therapeutic approaches to neuroblastoma and other embryonal tumors of children. Specific pilot studies will include a phase I study of Gallium Nitrate, a phase I Study of 9-cis retinoic acid and novel cell cycle based therapeutic approaches to neuroblastoma involving chemosensitization with growth factor antagonists. (2) enhance minority participation in POG studies and in particular phase I studies. (3) continue to provide leadership in POG in the areas of pharmacology, neuroblastoma, bone tumors, bone marrow transplantation and non-Hodgkin's lymphoma (4) participate in the administrative functions of POG in the areas of bone marrow transplantation, new agents and pharmacology and non-Hodgkin's lymphoma.